Overlap syndrome: additive effects of COPD on the cardiovascular damages in patients with OSA.
The chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) have been recently much focused as independent risks for cardiovascular disease. Furthermore, the complication of both has a worse prognosis compared with patients with only one of these diseases. However, the details of the underlying mechanisms of this worsened prognosis have not been clear. The cross-sectional study was conducted to examine whether the overlap of COPD augment the increase in arterial stiffness in subjects with OSA. If so, we examined the exaggeration of nocturnal hypoxemia and its related inflammation are related to this augmentation of increased arterial stiffness. In 524 male subjects with OSA diagnosed by polysomnography (apnea-hypopnea index >5/h) (52 ± 14 years old), the forced expiratory volume at 1 s/the forced vital capacity (FEV(1)/FVC) ratio, brachial-ankle pulse wave velocity (baPWV), blood C-reactive protein (CRP) and B-natriuretic peptide (BNP) levels were measured. The prevalence rate of COPD was 12% in this study subjects. Plasma BNP levels and the crude (median value, 17.2 vs. 14.1 m/s, p < 0.01) and adjusted value of baPWV were significantly higher in subjects with overlap syndrome than in those with OSA alone. However, parameters of nocturnal hypoxemia and serum CRP levels were similar between both groups. Thus, the overlap of COPD in patients with OSA augments increase in arterial stiffness without the exaggeration of nocturnal hypoxemia and inflammation. Even so, this augmentation may partially contribute to the increased cardiovascular risk in the overlap syndrome.
Department of Cardiology, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
Kazuki
K
Shiina
Hirofumi
H
Tomiyama
Yoshifumi
Y
Takata
Masanobu
M
Yoshida
Kota
K
Kato
Yosuke
Y
Nishihata
Chisa
C
Matsumoto
Mari
M
Odaira
Hirokazu
H
Saruhara
Yuki
Y
Hashimura
Yasuhiro
Y
Usui
Akira
A
Yamashina
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D002423:Cause of Death; D015331:Cohort Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000401:mortality; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000401:mortality
D000959:Antihypertensive Agents